A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by L. braziliensis

(1)Instituto Gonçalo Muniz, FIOCRUZ, Salvador, BA, Brazil.

(2)Uniara, Araraquara, SP, Brazil.

(3)Serviço de Imunologia, HUPES-UFBA, Salvador, BA, Brazil.; INCT - Instituto de Investigação em Doenças Tropicais, Salvador, BA, Brazil.

(4)Instituto Gonçalo Muniz, FIOCRUZ, Salvador, BA, Brazil; Serviço de Imunologia, HUPES-UFBA, Salvador, BA, Brazil.; INCT - Instituto de Investigação

em Doenças Tropicais, Salvador, BA, Brazil.

(5)Instituto Gonçalo Muniz, FIOCRUZ, Salvador, BA, Brazil; INCT - Instituto de Investigação em Doenças Tropicais, Salvador, BA, Brazil. 

The treatment of cutaneous leishmaniasis (CL) in Brazil using pentavalent antimony (Sbv) is associated with a high failure rate and long time to heal. Moreover, standard Sbv treatment cures only 50-60% of the cases. In this pilot clinical trial, we evaluated the topical use of bacterial cellulose (BC) bio-curatives + Sbv in the treatment of CL caused by L. braziliensis, in Bahia, Brazil. A total of 20 patients were randomized in two groups assigned to receive either parenteral Sbv alone or parenteral Sbv plus topically applied BC bio-curatives. CL patients treated with Sbv + topical BC bio-curatives had a significantly higher cure rate at 60 days post initiation of treatment compared to CL patients treated with Sbv alone (P=0.01). At day 90 post initiation of treatment, cure rate was similar in the two groups as was overall healing time. Adverse effects or local reactions to topical BC application were not observed. This pilot trial shows that the potential use of a combined therapy consisting of topical BC bio-curatives and parenteral Sbv in favoring healing of CL lesions caused by L. braziliensis, at an early time point.